Oscar Health Inc. Class A Common Stock (OSCR)

FairStock Score: 31/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Oscar Health as a Graham-style defensive investor would: what am I getting for $33.79 at the 2026-10-13 close? The market cap is $11.3B, P/E 25.99, P/B 5.07, and the Graham Number is $13.95. That leaves a margin of safety of -142.22%, meaning the price is not supported by conservative asset and earnings math. The Lynch category is TURNAROUND—loss in the latest year after earlier profits—and FY2025 filed net income was -$443.2M after FY2024's $25.4M. Yet recent quarters look radically better: fiscal Q1 2026 net income was $679.0M, and fiscal Q2 2026 net income was $361.8M. Revenue growth of 52.55% and profit growth of 146.66% are spectacular, and PEG 0.18 suggests the market is not paying much for that growth if it is real. The TTM FCF of $4.4B and 38.9% FCF yield are striking, but insurance cash flows can be seasonal and reserve-sensitive; I would not capitalize them blindly. Financial quality is mixed: ROE 34.26% is high and D/E 0.23 is modest, but ROCE is only 4.47%, Piotroski is 4/9, Altman Z-Score is 0.89, and the FairStock Score is 31/100. Beta 2.37 means the market treats this as volatile. The company may be a genuine turnaround, but the price already reflects a lot of good news. I want a durable underwriting profit, not just one or two strong quarters.

In plain English: Oscar Health sells health insurance plans and health technology to individuals, families, employees, and small groups. The business had a loss in its latest full year but has reported profits in more recent quarters, and it is growing quickly. At the current price, the stock looks expensive compared with the company's assets and profits, and the recent profits need to hold up.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer